Zoltan Vajo

Budapest, BU 1085, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Preparing for the Next Potential Pandemic-Chikungunya, Dengue, Zika and Other Viruses.

Preparing for the Next Potential Pandemic-Chikungunya, Dengue, Zika and Other Viruses.

Journal: Viruses

Published: December 19, 2025

Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection.

Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection.

Journal: Viruses

Published: September 18, 2024

Evaluation of Vaccine Immunogenicity-Correlates to Real-World Protection: Influenza.

Evaluation of Vaccine Immunogenicity-Correlates to Real-World Protection: Influenza.

Journal: Viruses

Published: January 22, 2024

Extinction of the Influenza B Yamagata Line during the COVID Pandemic-Implications for Vaccine Composition.

Extinction of the Influenza B Yamagata Line during the COVID Pandemic-Implications for Vaccine Composition.

Journal: Viruses

Published: August 01, 2022

Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.

Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.

Journal: Viruses

Published: January 14, 2022

A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients.

A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients.

Journal: Viruses

Published: February 20, 2021

Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial.

Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial.

Journal: Vaccine

Published: July 18, 2018

Safety data of the new, reduced-dose influenza vaccine FluArt after its first season on the market

Safety data of the new, reduced-dose influenza vaccine FluArt after its first season on the market

Journal: Orvosi hetilap

Published: December 05, 2017

Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial.

Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial.

Journal: British journal of clinical pharmacology

Published: November 04, 2016

Protection of Chinese painted quails (Coturnix chinensis) against a highly pathogenic H5N1 avian influenza virus strain after vaccination.

Protection of Chinese painted quails (Coturnix chinensis) against a highly pathogenic H5N1 avian influenza virus strain after vaccination.

Journal: Archives of virology

Published: March 11, 2013

A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.

A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.

Journal: Clinical and vaccine immunology : CVI

Published: January 06, 2012

The seasonal influenza vaccine Agriflu(®).

The seasonal influenza vaccine Agriflu(®).

Journal: Expert review of vaccines

Published: November 03, 2011

Showing 1-12 of 16

Last Updated: 09/26/2026